




Novel intestinal topical agonists of the TGR5 bile acids receptor for the treatment of the Type 2 diabetes and its metabolic complications

Technology

Activation of TGR5 receptor is recognized for stimulating the secretion of incretin GLP1.

Increased secretion of GLP 1 is used as a treatment of type 2 diabetes thanks to GLP-like products (Victoza, Byetta)



Benefits

- Topical Molecules (very low systemic leakage)
- POC in vivo for the secretion of endogenous GLP-1, improvement of insulin resistance, fasting glycemia and insulinemia, and weight lost in acute and chronic administration in diabetic mice model.
- Orally active
- No toxic effect, particularly on gallbladder

Applications

- Treatment of Type 2 diabetes and its metabolic complications, as well as possibly any other disease involving TRG5 receptor

Keywords

- TGR5 Topical agonists
- Type 2 diabetes

Intellectual Property

2 PCT applications :
WO 2015/189330
WO 2016/016238

2 Priority patent applications
filed in September 2015 and
February 2016

Development Status

Preclinical

Partnership

Licencing / partnership

contact

Anthony DACCACHE, Ph.D.
Business Developer
+33 6 13 84 39 39
anthony.daccache@sattnord.fr

find other technologies on
www.sattnord.fr

SATT Nord
25, avenue Charles St Venant – 59800 LILLE – France
+33 3 28 36 04 68 – tech@sattnord.fr